GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Drug-drug Interaction Study of Gepotidacin

Phase 1

Completed

Conditions: Infections, Bacterial

Interventions: Drug: Gepotidacin
Other: Placebo matching to gepotidacin
Drug: Midazolam
Drug: Cimetidine
Drug: Rifampicin
Drug: Digoxin

First Posted Date: 2020-07-30

Last Posted Date: 2022-03-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 64

Registration Number: NCT04493931

Locations: 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States

Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.

Phase 1

Completed

Conditions: Urinary Tract Infections

Interventions: Drug: GSK3882347
Drug: Placebo

First Posted Date: 2020-07-28

Last Posted Date: 2023-02-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 61

Registration Number: NCT04488770

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Bortezomib

First Posted Date: 2020-07-23

Last Posted Date: 2025-03-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 302

Registration Number: NCT04484623

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: Niraparib
Biological: Pembrolizumab
Drug: Placebo

First Posted Date: 2020-07-17

Last Posted Date: 2025-01-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 666

Registration Number: NCT04475939

Locations: 🇬🇧
GSK Investigational Site, Wrexham, United Kingdom

A Clinical Study to Assess Force Required to Dislodge Upper Denture With and Without Use of a Novel Denture Adhesive

Phase 3

Withdrawn

Conditions: Denture Retention

Interventions: Device: Super Poligrip Free
Device: Investigational denture adhesive cream

First Posted Date: 2020-07-16

Last Posted Date: 2021-01-22

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT04473521

Locations: 🇺🇸
Indiana University School of Dentistry, Indianapolis, Indiana, United States

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants

Phase 1

Terminated

Conditions: Tuberculosis

Interventions: Drug: Placebo
Drug: GSK2556286

First Posted Date: 2020-07-16

Last Posted Date: 2025-05-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 92

Registration Number: NCT04472897

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

Phase 2

Completed

Conditions: Hepatitis B

Interventions: Drug: GSK3228836
Drug: Placebo
Drug: Nucleos(t)ide therapy

First Posted Date: 2020-06-26

Last Posted Date: 2023-05-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 457

Registration Number: NCT04449029

Locations: 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: GSK6097608
Drug: Dostarlimab
Drug: Belrestotug
Drug: Cobolimab

First Posted Date: 2020-06-24

Last Posted Date: 2025-03-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 107

Registration Number: NCT04446351

Locations: 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of

Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3

Terminated

Conditions: Neoplasms, Head and Neck

Interventions: Drug: Feladilimab
Drug: Pembrolizumab
Drug: Placebo
Drug: Platinum based chemotherapy
Drug: Fluorouracil (5FU)

First Posted Date: 2020-06-11

Last Posted Date: 2024-10-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 117

Registration Number: NCT04428333

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)

Phase 2

Completed

Conditions: Infections, Soft Tissue

Interventions: Biological: Sa-5Ag half dose non-adjuvanted
Biological: Sa-5Ag full dose non-adjuvanted
Biological: Placebo
Biological: Sa-5Ag half dose adjuvanted
Biological: Sa-5Ag full dose adjuvanted

First Posted Date: 2020-06-09

Last Posted Date: 2025-05-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 226

Registration Number: NCT04420221

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

Home Terms & Conditions Privacy Policy